RWE is FurNavi's ultimate strategic asset: every de-identified dataset on the platform accelerates drug development and licensing.
Taiwan pet healthcare total addressable market
Serviceable available market
Initial serviceable obtainable market
At 1,000 RWE cases, the dataset becomes valuable for initial licensing and publication — Star Program clinics share the benefits first.
12,000 structured clinical cases can save 40–60% of clinical development cost and shorten the pre-IND phase.
MIRAGENIX serves the animal healthcare market with a "Device × Platform × CDMO / New Drug" trinity.
Miracle Biomedical received FDA IND for its MSC frailty therapy in June 2026 (dual filing) — validating the group's regenerative medicine capability.
Device acquisition, platform revenue, data accumulation, R&D conversion — a sustainable clinical data flywheel.
Real-world evidence supports veterinary drug and regenerative medicine development, shortening cost and time to clinic.
RWE is FurNavi's ultimate strategic asset — we invite strategic partners and investors to join us.
Contact Us